Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims

A class action lawsuit was filed against Corcept Therapeutics CORT +4.14% ▲ on February 20, 2026.

End of Quarter Sale - 50% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Plaintiffs -shareholders- in the federal securities class action allege that they acquired Corcept stock at artificially inflated prices between October 31, 2024, and December 30, 2025, known as the “Class Period.” They are now seeking compensation for financial losses incurred upon public revelation of the company’s alleged misconduct during that time. To learn whether you may be eligible for a recovery under this securities lawsuit, click here.

What Does Corcept Therapeutics Do?

Corcept is a commercial-stage company focusing on identifying and developing medications for the treatment of severe conditions affecting the endocrine system, metabolism, brain and nervous system, as well as cancer. Specifically, it does this by “modulating the effects of the hormone cortisol.” To that end, the company also says its portfolio of proprietary compounds “selectively modulate the effects of cortisol but not progesterone.”

As the company explains, the adrenal gland produces cortisol, a glucocorticoid known as the “stress hormone.” However, the pituitary gland regulates this steroid hormone, which is responsible for adjusting physical and psychological processes throughout the body. Among other things, it plays a part in suppressing inflammation, regulating blood pressure and blood sugar. It can also influence thought processes and emotions. Continually elevated or poorly regulated cortisol activity can lead to serious illnesses, the company says.

According to the complaint, relacorilant, is one of the company’s lead new product candidates. It is being developed  as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”), among other conditions. The company’s claims about relacorilant are at the crux of the current complaint.

Why are Corcept Shareholders Angry?

The company and four of its senior executives (the “Officer Defendants”) are now accused of deceiving investors by lying and withholding important information about Corcept’s business and prospects during the Class Period.

Specifically, they are accused of omitting truthful information about the New Drug Application (“NDA”) for relacorilant from SEC filings and related material. By knowingly or recklessly doing so, they allegedly caused the company’s stock to trade at artificially inflated prices during the time in question.

The truth, according to shareholders, came out on December 31, 2025. That’s when the company issued a press release disclosing that Corcept revealed that the U.S. Food and Drug Administration (“FDA”)  had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. Among other things, the press release stated that the FDA had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”

Taking a Closer Look

As alleged, Corcept and/or the Individual Defendants repeatedly made false and misleading public statements throughout the Class Period.

During an earnings call held at the beginning of the Class Period, for instance, the company’s CEO, an Individual Defendant, stated in pertinent part: “[the] “results from our GRACE and GRADIENT Phase 3 studies clear the path for relacorilant’s new drug application in Cushing’s syndrome, which we will submit by year-end.”

Next, in a December 30, 2024 press release, the company’s CEO stated in relevant part: “Relacorilant’s combination of efficacy and safety give it the potential to become the standard of care for the medical treatment of patients with hypercortisolism.”

Lastly, during a November 4, 2025 earnings call, the President of Corcept’s Endocrinology Division, an Individual Defendant, stated in pertinent part: “[i]n the next three to five years, I believe relacorilant will generate $3 billion to $5 billion in annual revenue in hypercortisolism alone.”

Actions You Can Take

If you have purchased the company’s stock during the Class Period, you may join the class action as a lead plaintiff, remain a passive class member, or opt out of this litigation and pursue individual claims that may not be available to the class as a whole. To learn more, click here.

The deadline to file for lead plaintiff in this class action is April 21, 2026.

Disclaimer & DisclosureReport an Issue